Report copyright - ESMO SUMMIT LATIN AMERICA 2019 · 2016. Ganten ESMO 2014. Median Overall Survival. Target: VEGF-1-3, PDGFR-b, KIT, FLT-3, and RET. Firstline. 2 Phase III Studies: SHARP, AP. 8 Phase
Please pass captcha verification before submit form